Clinical trial NCT00583349 (phase 1/phase 2, status: unknown status)
Conditions: bladder cancer
ICD codes: D30.3, C67.5, C67.9, C79.11, C67.0, C67.1, D41.4
Drugs: paclitaxel, nanoparticle albumin-bound
SMILES: [H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C
Eligibility criteria:

        Inclusion Criteria:

          -  Patients must have a diagnosis of transitional cell carcinoma (TCC) of the urinary
             bladder confirmed at the study institution. The patient must have demonstrated
             superficial recurrent bladder cancer refractory to standard intravesical therapy. This
             will include stage Ta, T1, Tis and exclude all patients with muscle invasion (T2). All
             patients with stage Ta will require documentation of high-grade histology. All grossly
             visible disease must be fully resected and pathologic stage will be confirmed at the
             institution where the patient is enrolled. Patients must exhibit disease recurrence
             after receiving some form of standard intravesical therapy, including BCG, mitomycin,
             interferon or any combination thereof.

          -  Age > 18 and must be able to read, understand and sign informed consent

          -  Performance Status: ECOG 0,1 (See Appendix II )

          -  Peripheral neuropathy: must be < grade 1

          -  Hematologic-Inclusion within 2 weeks of start of treatment

               -  Absolute neutrophil count > 1,500/mm3

               -  Hemoglobin >9.0 g/dl

               -  Platelet count > 100,000/mm3

          -  Hepatic-Inclusion within 2 weeks of entry

               -  Total Bilirubin must be within normal limits.

               -  Adequate renal function with serum creatinine ≤ 2.0 mg/dL

               -  Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 2.5 x ULN for the
                  institution, Alkaline phosphatase ≤ 2.5 x ULN for the institution, unless bone
                  metastasis is present in the absence of liver metastasis

          -  Women of childbearing potential must have a negative pregnancy test.

          -  All patients of childbearing potential must be willing to consent to using effective
             contraception, i.e., IUD, Birth control pills, Depo-Provera, and condoms while on
             treatment and for 3 months after their participation in the study ends.

          -  No intravesical therapy within 6 weeks of study entry

          -  No prior radiation to the pelvis

        Exclusion Criteria:

          -  Prior systemic docetaxel or paclitaxel therapy.

          -  Any other malignancy diagnosed within 2 years of study entry (except basal or squamous
             cell skin cancers or non-invasive cancer of the cervix) is excluded.

          -  Concurrent treatment with any chemotherapeutic agent.

          -  Women who are pregnant or lactating.

          -  History of vesicoureteral reflux or an indwelling urinary stent.

          -  Participation in any other research protocol involving administration of an
             investigational agent within 3 months prior to study entry aside from the phase I
             segment of this study.

          -  History of neuropathy of any cause